AstraZeneca therapy works against Omicron; results mixed for Regeneron
By Mrinalika Roy and Pushkala Aripaka (Reuters) – AstraZeneca and Regeneron on Thursday reported contrasting data on the effectiveness of their COVID-19 antibody therapies against the Omicron variant of the coronavirus, underscoring the major challenges ahead for drugmakers. U.S.-based Regeneron said its REGEN-COV therapy, also called Ronapreve, is less effective against Omicron, though it is …
AstraZeneca therapy works against Omicron; results mixed for Regeneron Read More »